Navigation Links
Neurologix Completes Additional $7 Million Financing
Date:12/6/2010

ny. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events, or performance, as well as underlying assumptions and statements that are other than statements of historical fact. When used in this document, the words "expects," "promises," "anticipates," "estimates," "plans," "intends," "projects," "predicts," "believes," "may" or "should," and similar expressions, are intended to identify forward-looking statements. These statements reflect the current view of the Company's management with respect to future events. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, but not limited to, the following:

  • The Company is still in the development stage and has not generated any revenues. From inception through September 30, 2010, it incurred net losses and negative cash flows from operating activities of approximately $58 million and $43 million respectively. Management believes that the Company will continue to incur net losses and cash flow deficiencies from operating activities for the foreseeable future. Because it may take years to develop, test and obtain regulatory approval for a gene-based therapy product before it can be sold, the Company likely will continue to incur significant losses for the foreseeable future. Accordingly, it may never be profitable and, if it does become profitable, it may be unable to sustain profitability.
  • The Company will need to conduct future clinical trials for treatment of Parkinson's disease using NLX-P101. If the trials prove unsuccessful, future operations and the potential for profitability will be materially adversely affected and the business may not succeed.
  • There is no assurance as to when, or if, the Company will be able to successfully re
    '/>"/>

  • SOURCE Neurologix, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related medicine technology :

    1. New Details Presented at the World Parkinson Congress on Neurologixs Successful Phase 2 Trial of Gene Therapy for Parkinsons Disease
    2. Research Published in Science Translational Medicine Underscores Value of Depression Gene Therapy License Held by Neurologix
    3. Neurologix Reports Third Quarter 2010 Financial Results
    4. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    5. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
    6. TaiGen Biotechnology Successfully Completes Patient Recruitment for Phase II Trial of Nemonoxacin for Treatment of Adult Community Acquired Pneumonia (CAP)
    7. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
    8. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
    9. QuatRx Completes Patient Enrollment in Phase 3 Study of Ophena(TM) in Women with Postmenopausal Vaginal Syndrome
    10. CryoCor Completes Enrollment of Pivotal Clinical Study for Atrial Fibrillation
    11. Anesiva Completes Enrollment in Phase 3 Clinical Trial of Zingo(TM) to Treat Pain Associated With Venous Access Procedures in Adults
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:1/15/2014)... AARP Foundation today announced it has established a ... severe cold weather that has gripped much of the nation. ... need; so to support these emergency relief efforts AARP and ... could mean up to $500,000 in aid. The matching program ...
    (Date:1/15/2014)... , January 15, 2014 Shire plc (LSE: SHP, ... Office of Fair Trading (OFT) approval condition to the announced tender ... VPHM).   As a result of the waiver, the ... to complete the tender offer on January 24, 2014 following the ...
    (Date:1/15/2014)... 2014  In an unprecedented effort to curb the spread of "superbugs" ... transport vehicles, an advanced and portable UV germicidal lamp manufactured by ... time. In order to prevent EMS paramedics and ... West Palm Beach Fire Rescue is the first ...
    Breaking Medicine Technology:AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 2AARP Foundation Establishes Winter Relief Fund for Older Adults Suffering from the Severe Cold Weather 3Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 2Shire Waives OFT Condition Relating to the Acquisition of ViroPharma Inc. 3Superbugs No Longer Ride In Rescue Vehicles 2
    ... 2011 Generex Biotechnology Corporation (OTCBB: GNBT) ( ... subsidiary Antigen Express, Inc. ( www.antigenexpress.com ) presented ... with an off-the-shelf immunotherapeutic cancer vaccine, AE37, in ... Sixth Annual ImVacS: The Immunotherapeutics and Vaccine Summit ...
    ... Inc. (Nasdaq: REGN ) today announced that clinical ... will be presented at the upcoming American Society of Retina ... 22, 2011 in Boston, Massachusetts. The presentations ... Phase 3 VIEW 1 and VIEW 2 Studies Comparing VEGF ...
    Cached Medicine Technology:Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 2Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 3Generex Subsidiary Antigen Express Provides Update on Phase 2 Breast Cancer Immunotherapy Program 4Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 2Regeneron Announces Clinical Presentations at ASRS 2011 Annual Meeting 3
    (Date:4/22/2014)... have characterized a set of clock genes that drive ... of species, from flies to humans. Over 15 mammalian ... are more. A team from the Perelman School of ... approaches could find them. , To accelerate clock-gene ... of Pharmacology and first author Ron Anafi, MD, PhD, ...
    (Date:4/22/2014)... April 22, 2014 Researchers at UT Southwestern Medical ... from depression . , A team of ... by which ghrelin (a hormone with natural anti-depressant properties) ... potentially powerful new treatment for depression in the form ... The study, published online in April,s issue of ...
    (Date:4/22/2014)... Calif.) The risk of pregnancy among women using ... is more than 10 times greater over a 10-year ... a study by researchers at Yale University and UC ... the medical journal Contraception , the study found ... method marketed under the brand name Essure. , ...
    (Date:4/22/2014)... Washington, DC (April 22, 2014) The International ... May 22-26 in Seattle, Washington. The theme of ... life" means in a networked and digital society. ... and attended by over 2,200 Communication scholars representing ... largest scholarly international communication conference in the world. ...
    (Date:4/22/2014)... is the standard measurement for assessing glycemic control over ... are typically measured every few months in a laboratory, ... accurately estimates A1c using self-monitored blood glucose (SMBG) readings, ... ( DTT ), a peer-reviewed journal from Mary Ann ... the DTT website at http://www.liebertpub.com/dtt . ...
    Breaking Medicine News(10 mins):Health News:Bioinformatics profiling identifies a new mammalian clock gene 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 2Health News:Depressed? Researchers identify new anti-depressant mechanisms, therapeutic approaches 3Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:International Communication Association to hold Annual Conference in Seattle, Washington 2
    ... suggests , , FRIDAY, Nov. 21 (HealthDay News) -- The season ... asthma, new research suggests. , Babies born in autumn -- about ... almost a 30 percent increased risk of asthma compared to babies ... the first December issue of the American Journal of Respiratory ...
    ... not given adequate drug therapy. This is the result of ... rzteblatt International ( Dtsch Arztebl Int 2008; 105[45]: ... this prospective, one-year survey. , 512 doctors in Germany took ... of whom 89.2% suffered from one or more cardiovascular diseases ...
    ... HUN ) today announced that its Founder and Chairman, ... American Cancer Society to,receive this year,s Medal of Honor, its ... who have made outstanding contributions to the,fight against cancer. , ... and his wife Karen Huntsman have "raised or,personally contributed over ...
    ... Nov. 21 Massachusetts Mutual Life,Insurance Company (MassMutual) ... Officers. , ... Vice President,and Chief Investment Officer, will assume the ... who remains Chairman and Chief Executive,Officer. Additionally, Mr. ...
    ... STOUGHTON, Mass., Nov. 21 Cardiosolutions, Inc.,( http://www.cardiosolutionsinc.com ... M.D., Ph.D. to the position of Chief Surgical ... Center for Aortic Surgery and Director of the,Marfan ... Department of,Thoracic and Cardiovascular Surgery at Cleveland Clinic. ...
    ... located in,Pittsburgh PA, and a subsidiary of Draeger, ... it believes are unsubstantiated allegations from,Sperian Respiratory Protection ... the popular Draeger PSS7000 SCBA (Self-Contained Breathing,Apparatus) used ... Draeger has a strong respect for intellectual ...
    Cached Medicine News:Health News:Autumn Babies More Prone to Asthma 2Health News:Autumn Babies More Prone to Asthma 3Health News:Jon M. Huntsman Receives American Cancer Society Medal of Honor 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 2Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 3Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 4Health News:MassMutual Announces Promotions for Two Co-Chief Operating Officers 5Health News:Cardiosolutions Names Dr. Lars Svensson Chief Surgical Officer 2Health News:Draeger Counters What It Believes Are Unsubstantiated Allegations of Patent Infringement by Sperian 2
    Phacoemulsification system is a complete anterior segment surgical instrument. Its simplified design and unique innovations provide optimal surgical performance....
    A gentle yet highly effective corneal rust ring remover with Alger brush of 1mm burr. Runs off 1 x AA battery, no switches, simply spin mandrel to operate....
    Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings....
    Foreign body removal system. Designed to aid in the removal of foreign bodies and corneal rust rings. Ophtho-burr handpiece only. Battery powered handpiece....
    Medicine Products: